BIOSGN — Biosergen AB Share News
0.000.00%
Last trade - 00:00- SEK40.77m
- SEK37.53m
Brief: Biosergen AB Says First Subject Dosed In Phase I Trial Of BSG005
Brief: Biosergen Q4 Consolidated Net Loss At SEK 15.0 Million
Brief: Biosergen Q3 Consolidated Net Loss SEK 6.7 Mln
Brief: Biosergen Q2 Net Loss At SEK 12.6 Million
Brief: Biosergen To Start Human Clinical Trials With BSG005
Brief: Biosergen Has Appointed Tine Kold Olesen As COO Of Co
Brief: Biosergen Says US FDA Grants BSG005 Orphan Drug Status